Oruka Therapeutics, Inc. (ORKA) Stock Score, Valuation & Financial Research

Oruka Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ORKA

Oruka Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 79.57. These figures are a research snapshot, not a buy or sell recommendation.

What Oruka Therapeutics, Inc. does

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Oruka Therapeutics is a clinical-stage biopharmaceutical company that has not yet commercialized any products or generated revenue. Its business model relies on funding operations through capital raises while developing a proprietary portfolio of antibodies for chronic skin diseases.

Products and services

  • The company is developing a pipeline of novel biologics, specifically ORKA-001 and ORKA-002, which are antibodies engineered to target IL-23 and IL-17A/F for the treatment of chronic skin conditions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to conduct clinical trials and development activities; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Paragon Therapeutics, Inc. — The company has entered into license agreements with Paragon to develop and commercialize antibody product candidates, including ORKA-001 and ORKA-002. Source

Business strengths to evaluate

  • Proprietary portfolio of potentially best-in-class antibodies Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses for the foreseeable future Source
  • Dependence on third-party collaborators and contract manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ORKA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 79.57
Market capitalization:
4.8B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -132.89M
Free cash flow:
USD -88.42M
Cash:
USD 268.47M
Total debt:
USD 2.55M
EPS:
USD -2.47

What stands out

  • Free cash flow is USD -88.42M, negative for the stored period.
  • The balance sheet shows USD 268.47M of cash versus USD 2.55M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 265.92M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ORKA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ORKA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ORKA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ORKA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ORKA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ORKA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.